OrbiMed Advisors WHWK Position
Active6-Fund ConvergenceOrbiMed Advisors held their position in Whitehawk Therapeutics, Inc. (WHWK) in Q4 2025, holding $10.1M worth of shares across 4,166,000 shares.
The position was first reported in Q1 2025 and has been tracked across 4 quarterly 13F filings.
WHWK is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
Full company profile →Short Interest
2.0%
4.3 days to cover
OrbiMed Advisors WHWK Position History
Frequently Asked Questions
Does OrbiMed Advisors own WHWK?
Yes. As of Q4 2025, OrbiMed Advisors holds 4,166,000 shares of Whitehawk Therapeutics, Inc. (WHWK) valued at $10.1M. This data comes from their SEC 13F filing.
How many hedge funds own WHWK?
6 specialist biotech hedge funds currently hold WHWK, including Avoro Capital Advisors, Baker Bros. Advisors, RA Capital Management and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy WHWK?
OrbiMed Advisors's position in WHWK was first reported in Q1 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's WHWK position increasing or decreasing?
OrbiMed Advisors held their WHWK position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
WHWKCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →